News & Filings
NATCOPHARM \u2014 Recent Activity
5 items in the last 14 days
India Sees 42 Drugmakers Launch Generic Semaglutide After Patent Expiry
Low-cost copies from major Indian firms could undercut Novo Nordisk pricing as competition rapidly expands across more than 50 brands.
Click to open →
Natco Pharma Ltd (BOM:524816) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and ...
Natco Pharma Ltd (BOM:524816) reports robust financial performance with a focus on emerging markets and future acquisitions.
Click to open →
Natco Pharma Ltd (BOM:524816) Q2 2026 Earnings Call Highlights: Strategic Wins and Future ...
Natco Pharma Ltd (BOM:524816) outlines its revenue expectations, strategic expansions, and innovative investments amidst competitive challenges.
Click to open →
India's stock benchmarks hit 10-week highs on Fed rate cut, optimism over US trade talks
India's benchmark shares rose on Thursday, closing at 10-week high levels, led by IT and pharmaceutical shares after the U.S. Federal Reserve delivered a quarter-point rate cut and on signs of easing trade tensions. The Nifty 50 gained 0.37% to 25,423.60, and the BSE Sensex rose 0.39% to 83,013.96. Shares of information technology and pharmaceutical firms, which earn a significant share of their revenue from the U.S., rose 0.8% and 1.5% respectively.
Click to open →
Natco Pharma Ltd (BOM:524816) Q4 2025 Earnings Call Highlights: Record Profits Amid Future ...
Natco Pharma Ltd (BOM:524816) reports its highest ever revenue and profits, while projecting a dip in FY26 due to geopolitical and market pressures.
Click to open →
Get alerts for important filings
Add NATCOPHARM to your watchlist for board meeting & dividend alerts.
Open analysis →News from yfinance + BSE corporate announcements. Importance scoring is automated. YieldIQ is not registered with SEBI as an investment adviser.